DK2470545T3 - Anhydrate former af et pyridinderivat - Google Patents

Anhydrate former af et pyridinderivat

Info

Publication number
DK2470545T3
DK2470545T3 DK10747619.4T DK10747619T DK2470545T3 DK 2470545 T3 DK2470545 T3 DK 2470545T3 DK 10747619 T DK10747619 T DK 10747619T DK 2470545 T3 DK2470545 T3 DK 2470545T3
Authority
DK
Denmark
Prior art keywords
pyridine derivative
anhydrate forms
anhydrate
forms
pyridine
Prior art date
Application number
DK10747619.4T
Other languages
Danish (da)
English (en)
Inventor
Andrew Simon Craig
Salima Zarah Ismail
Ronnie Maxwell Lawrence
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Application granted granted Critical
Publication of DK2470545T3 publication Critical patent/DK2470545T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK10747619.4T 2009-08-27 2010-08-25 Anhydrate former af et pyridinderivat DK2470545T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23743509P 2009-08-27 2009-08-27
PCT/EP2010/062420 WO2011023733A1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
DK2470545T3 true DK2470545T3 (da) 2014-01-13

Family

ID=42790943

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10747619.4T DK2470545T3 (da) 2009-08-27 2010-08-25 Anhydrate former af et pyridinderivat

Country Status (18)

Country Link
US (1) US8796269B2 (enEXAMPLES)
EP (1) EP2470545B1 (enEXAMPLES)
JP (3) JP2013503134A (enEXAMPLES)
KR (1) KR20120056258A (enEXAMPLES)
CN (1) CN102639536B (enEXAMPLES)
AU (1) AU2010288502B2 (enEXAMPLES)
BR (1) BR112012003435A2 (enEXAMPLES)
CA (1) CA2772168C (enEXAMPLES)
DK (1) DK2470545T3 (enEXAMPLES)
EA (1) EA021411B1 (enEXAMPLES)
ES (1) ES2440938T3 (enEXAMPLES)
IL (1) IL217922A (enEXAMPLES)
IN (1) IN2012DN01292A (enEXAMPLES)
MX (1) MX2012002369A (enEXAMPLES)
PL (1) PL2470545T3 (enEXAMPLES)
SG (1) SG178231A1 (enEXAMPLES)
WO (1) WO2011023733A1 (enEXAMPLES)
ZA (1) ZA201200812B (enEXAMPLES)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012002369A (es) * 2009-08-27 2012-03-29 Glaxosmithkline Llc Formas de anhidrato de un derivado de piridina.
ES2879375T3 (es) 2014-06-25 2021-11-22 Univ Emory Procedimientos de manejo del miedo condicionado con antagonistas del receptor de neuroquinina
MX377052B (es) * 2015-05-18 2025-03-07 Kandy Therapeutics Ltd Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
WO2018109646A1 (en) * 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 compounds
RS65257B1 (sr) * 2018-03-14 2024-03-29 Kandy Therapeutics Ltd Nova farmaceutska formulacija koja sadrži dvojne antagoniste receptora nk-1/nk-3
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
AU2020381762A1 (en) * 2019-11-15 2022-06-02 KaNDy Therapeutics Limited New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814
EP4431512A1 (en) 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2359235T3 (es) * 1999-02-24 2011-05-19 F. Hoffmann-La Roche Ag Derivados de 4-fenilpiridina y su empleo como antagonistas del receptor nk-1.
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
ATE366576T1 (de) * 2003-01-31 2007-08-15 Hoffmann La Roche Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-
WO2005002577A1 (en) * 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
MY145713A (en) * 2005-09-09 2012-03-30 Smithkline Beecham Corp Hexahydropyrazino [2,1-c][1,4]oxazin-8(1h)-yl pyridine derivatives and their use in the treatment of psychotic disorders
AU2008346110A1 (en) * 2007-12-11 2009-07-16 Cipla Ltd. Crystalline polymorphic forms of zopiclone, processes for their preparation and their pharmaceutical compositions
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
MX2012002369A (es) * 2009-08-27 2012-03-29 Glaxosmithkline Llc Formas de anhidrato de un derivado de piridina.
JP6342662B2 (ja) * 2014-01-29 2018-06-13 京セラ株式会社 ドリルおよびそれを用いた切削加工物の製造方法

Also Published As

Publication number Publication date
CN102639536B (zh) 2015-03-18
AU2010288502B2 (en) 2013-12-12
BR112012003435A2 (pt) 2016-02-23
JP2017193564A (ja) 2017-10-26
MX2012002369A (es) 2012-03-29
JP2013503134A (ja) 2013-01-31
JP6404186B2 (ja) 2018-10-10
EA201270302A1 (ru) 2012-07-30
ES2440938T3 (es) 2014-01-31
JP2016000739A (ja) 2016-01-07
CA2772168A1 (en) 2011-03-03
US8796269B2 (en) 2014-08-05
IL217922A0 (en) 2012-03-29
WO2011023733A1 (en) 2011-03-03
CA2772168C (en) 2019-01-08
EP2470545B1 (en) 2013-10-09
PL2470545T3 (pl) 2014-03-31
IL217922A (en) 2016-06-30
EA021411B1 (ru) 2015-06-30
AU2010288502A1 (en) 2012-02-23
ZA201200812B (en) 2013-03-27
IN2012DN01292A (enEXAMPLES) 2015-06-05
CN102639536A (zh) 2012-08-15
EP2470545A1 (en) 2012-07-04
KR20120056258A (ko) 2012-06-01
SG178231A1 (en) 2012-03-29
US20120157450A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
HUS2000005I1 (hu) Diamino-heterociklusos karboxamid-vegyület
EP2404918A4 (en) pyridine
EP2519522A4 (en) SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS
DK2262793T3 (da) Krystallinske former af nilotinib-hci
DK2470545T3 (da) Anhydrate former af et pyridinderivat
HRP20180646T1 (hr) Dispiropirolidinski derivat
DK2268160T3 (da) Emulsioner omfattende et PEG-derivat af tokoferol
ECSP12011999A (es) Derivados benzamida sustituidos
DK3703369T3 (da) Fusion af prøveområder
FI20095666A0 (fi) Hitsauksen optimointi
DK2404485T3 (da) Automatisk konfigurering af en belysning
BRPI1011683A2 (pt) derivado isoquinolina substituída
DK2260153T3 (da) Brandbeskyttelse af et strukturelt element
EP2404030A4 (en) RECOVERING WELL REINFORCING MATERIAL
EP2397480A4 (en) DIAZEPINEDIONEDERIVATE
EP2508513A4 (en) 2-PYRIDONES COMPOUNDS
BR112012005960A2 (pt) n-fenil-1-(4-piridinil)-1h-pirazol-3-aminas substituídas
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
BR112012002807A2 (pt) derivados de 5-flúor-2-oxopirimidina-1(2h)-caboxilato
SMT201500268B (it) Derivato di 5-idrossipirimidin-4-carbossammide
EP2519519A4 (en) Substituted Naphthalenyl-pyrimidine compounds
PL2488157T3 (pl) Ulepszone preparaty
DK2217006T3 (da) Et høreapparat
DK2302952T3 (da) Selvtilpasning af et hørehjælpeapparat
CO6970612A2 (es) Derivados de alcanol heterocíclicos novedosos